Jan 08, 2020 / 01:15PM GMT
Operator
Good morning, and welcome to the SCYNEXIS Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the call over to Troy Neubecker of Investor Relations. You may begin.
Troy Neubecker;Argot Partners;Investor Relations -
Good morning, and thank you for joining us as we report positive results from the second interim analysis of our ongoing Phase III open-label FURI of -- study -- FURI study of oral Ibrexafungerp as a salvage treatment for difficult-to-treat invasive fungal infections.
Joining me today are Dr. Marco Taglietti, President and Chief Executive Officer; Dr. David Angulo, Chief Medical Officer; and Eric Francois, Chief Financial Officer.
During this call, please note we will be making forward-looking statements. These statements are subject to factors, risks and uncertainties, including those that are detailed in today's presentation and our Form 10-K for the year ended December 31, 2018, as well as our subsequent SEC filings that may
SCYNEXIS, Inc. - Special Call Transcript
Jan 08, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers